AH
ESPR

Aviva Holdings’s Esperion Therapeutics ESPR Stock Holding History

Aviva Holdings’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-441,649
Closed -$17.7M – 6
2019
Q1 		$17.7M Sell
441,649
-23,000
-5% -$1.03M 3.89% 4
2018
Q4 		$21.4M Sell
464,649
-735,451
-61% -$35.4M 6.74% 4
2018
Q3 		$53.2M Hold
1,200,100
– – 14.21% 3
2018
Q2 		$47M Buy
1,200,100
+1,032,513
+616% +$52.2M 7.64% 4
2018
Q1 		$12.1M Sell
167,587
-121,513
-42% -$8.92M 4.92% 4
2017
Q4 		$14.5M Hold
289,100
– – 8.49% 4
2017
Q3 		$14.5M Sell
289,100
-50,900
-15% -$2.45M 7.53% 3
2017
Q2 		$15.7M Hold
340,000
– – 9.92% 2
2017
Q1 		$12M Buy
+340,000
New +$7.79M 5.6% 3

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Aviva Holdings's ESPR Position: Q2 2019 in Review

Aviva Holdings sold out of Esperion Therapeutics (ESPR) in Q2 2019, closing a stake of 441,649 shares — an estimated $17.7M sold.

Aviva Holdings first reported a position in ESPR in Q1 2017 and held it in 9 quarters. The position peaked at $53.2M in Q3 2018. 167 funds tracked by Wall St. Rank hold ESPR as of Q2 2019.

  • Aviva Holdings reported no remaining Esperion Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Aviva Holdings sold 441,649 Esperion Therapeutics shares in Q2 2019, an estimated $17.7M.
  • Aviva Holdings first reported a position in Esperion Therapeutics in Q1 2017 and held it in 9 quarters.
  • Aviva Holdings's Esperion Therapeutics position peaked at $53.2M in Q3 2018.
  • 167 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2019.

Based on Aviva Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.